Depomed Targets Generics Maker Over Diabetes Drug IP

Law360, Los Angeles (March 1, 2013, 9:33 PM EST) -- Pharmaceutical company Depomed Inc. filed a patent infringement suit Thursday in Delaware federal court against Watson Laboratories Inc., saying the company’s planned generic version of Depomed’s extended-release metformin drug Glumetza for Type II diabetes violates four patents.

Menlo Park, Calif.-based Depomed brought suit after Watson, and its subsidiaries Actavis Inc. and Watson Pharmaceuticals Inc., sought federal approval of an abbreviated new drug application to make and sell a generic version of Glumetza before Depomed’s four patents had expired.

Thursday’s suit, which was filed within 45 days...
To view the full article, register now.